Research and Markets: Strategic Overview of Spondyloarthropathies: Tapping the Market Opportunity of Niche Immune Diseases

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/4fb491/strategic_overview) has
announced the addition of Decision Resources, Inc.'s new report "Strategic
Overview of Spondyloarthropathies: Tapping the Market Opportunity of Niche
Immune Diseases" to their offering.

A trio of niche immune diseases have gained drug developers' attention after a
period of strong sales growth. Treatment of these diseases, the
spondyloarthropathies (SpAs), was revolutionized by the availability of
TNF-alpha inhibitors and in turn these diseases proved to be a source of
additional sales for these blockbuster agents. The sales trend, and the limited
competition and remaining unmet needs in these indications, has prompted drug
developers to consider whether and how to pursue these markets.

Get the Answers You Need to Shape Your Strategy

* Although ankylosing spondylitis, psoriatic arthritis, and reactive arthritis
are grouped together as SpAs, treatment approaches have varied. What are the
current first-, second, and third-line therapies for these indications? What are
their unique etiological components and unmet needs? What kind of efficacy and
uptake have biologics seen in each indication?
* The SpAs are underdiagnosed and undertreated. What are the symptoms of these
diseases? How are they diagnosed? How many people in the United States and
Europe have an SpA? How will this population grow over the next ten years?
* Because of the high cost and increased use of TNF-alpha inhibitors, the SpA
market overall has experienced strong growth over the past few years. How large
is the SpA market? Will this market continue to grow? What new agents are in the
pipeline for these diseases, and how will these agents perform in the market?
* In April 2009, the FDA approved Simponi
(Centocor/Schering-Plough/Janssen/Mitsubishi Tanabe's golimumab) for RA, AS, and
PsA. What are this agent's advantages? How do surveyed rheumatologists expect to
use it in their medical practice?

Scope

* Primary research: Three disease-specific surveys of more than 100 U.S.
rheumatologists.
* Overview of SpAs: Etiology, symptoms, and diagnosis.
* Current treatments and medical practice: NSAIDs, DMARDs, TNF-a inhibitors,
corticosteroids, bisphosphonates; SpA treatment goals; first, second, and third
lines of therapy; therapy switching trends.
* Epidemiology: Decision Resources epidemiology, disease-specific patient
populations, ten year growth forecasts, epidemiology methodology.
* Emerging agents: Centocor/Schering-Plough/Janssen/Mitsubishi Tanabe's
golimumab, approved by the FDA in April 2009; and the following developmental
agents: Novartis's AIN-457, Pozen/AstraZeneca's PN-200 and PN-400, Bristol-Myers
Squibb's Orencia, Centocor/Medarex's Stelara, Array Biopharma's ARRY-371797,
Celgene's apremilast
* Market overview: 2008 AS, PsA, ReA, and undifferentiated SpA markets; outlook
for current and emerging agents.
* Geographic scope: Six major markets-United States, France, Germany, Italy,
Spain, United Kingdom.

Key Topics Covered:

Executive Summary

1. Introduction

2. Overview of the Spondyloarthropathies

3. Epidemiology

4. Current Treatment Approaches

5. Emerging Therapies for Spondyloarthropathies

6. 2008 Market and Future Market Considerations

Companies Mentioned:

* Abbott
* Amgen
* Array BioPharma
* Astellas
* AstraZeneca
* Boehringer Ingelheim
* Bristol-Myers Squibb
* Celgene
* Centocor
* Daiichi Sankyo
* Dava Pharmaceuticals
* Eisai
* GlaxoSmithKline
* Janssen
* Johnson & Johnson
* Medarex
* Merck
* Mitsubishi Tanabe
* Novartis
* Ovation
* Pfizer
* Pozen
* Procter & Gamble
* Sanofi -Aventis
* Schering-Plough
* Takeda
* UCB
* Wyeth

For more information visit
http://www.researchandmarkets.com/research/4fb491/strategic_overview

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009